A carregar...
The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure
In this phase 2, multicenter, parallel‐group, double‐blind, dose‐ranging study, hypertensive adults (n=449) were randomized to receive one of five doses of a capsule formulation of azilsartan medoxomil (AZL‐M; 5, 10, 20, 40, 80 mg), olmesartan medoxomil (OLM) 20 mg, or placebo once daily. The primar...
Na minha lista:
| Publicado no: | J Clin Hypertens (Greenwich) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8031072/ https://ncbi.nlm.nih.gov/pubmed/27558280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.12895 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|